Acrivon Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Acrivon Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 17, 2026, to elect directors and ratify auditor appointment.
NASDAQ
Acrivon Therapeutics announces its annual stockholders meeting to be held virtually on June 13, 2025, focusing on director elections and auditor ratification.
NASDAQ
Acrivon Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 13, 2025, featuring the election of Class III directors and ratification of the independent auditor.
NASDAQ
Acrivon Therapeutics will hold its annual meeting of stockholders on June 20, 2024, to elect directors and ratify the appointment of PricewaterhouseCoopers LLP as its independent accounting firm.
NASDAQ
DEF 14A: Acrivon Therapeutics Sets Date for 2024 Annual Stockholders Meeting, Outlines Key Proposals
Acrivon Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 20, 2024, featuring the election of Class II directors and ratification of the independent auditor.